Novartis stock jumped early Tuesday on better-than-expected second-quarter metrics, partially driven by Cosentyx.
Novartis Bounds For Buy Point. Why Shares Are On The Rise.
Licensing
08:48 AM ET 07/21/2026
Novartis (NVS) stock jumped early Tuesday after the drugmaker reported core earnings of $2.41 per share on $14.41 billion in second-quarter sales. On average, analysts surveyed by FactSet expected Novartis to earn $2.17 a share and report $14.07 billion in sales. During the year-earlier period, Novartis earned $2.42 a share on $14.05 billion in sales. Some of its biggest products,…
Why Is Novartis Stock Gaining Tuesday? - Novartis (NYSE:NVS)
Novartis climbs on upbeat drug sales as key readouts loom
Novartis says buoyed by new treatments in second quarter
Der Pharmakonzern Novartis verjüngt sein Geschäft geschickt
Novartis supera le attese, BofA conferma buy: i 5 studi clinici di fase III da seguire nel secondo semestre 2026 | MilanoFinanza News
Novartis supera estimativas no 2º trimestre, mas mantém cautela nas estimativas
Healthcare Shares Rise — Healthcare Roundup
Novartis shares rise as strong Q2 demand for key growth drugs offsets generic competition. NVS beats Q2 earnings and reaffirms…
A return to quarterly sales growth boosted shares higher on Tuesday, though a handful of coming study results will have a bigger…
Swiss pharmaceuticals giant Novartis said Tuesday that group sales exceeded expectations in the second quarter of 2026, on the…
Novartis on Thursday forecast sales growth of 5% to 6% per year to 2030, on a currency-adjusted basis, as sales for cancer drugs…
Trotz hohen Einbussen beim nicht mehr patentgeschützten Herzmittel Entresto ist Novartis schon wieder auf Wachstumskurs. An der…
Novartis will pay up to $400 million in potential additional payments. "Novartis to Buy Myricx Bio for Up to $1.5 Billion," at…
